Physician profile
Grazyna Piekos
NPI 1780605899
$29,611.83
in general payments reported to CMS, 2019-2025
67 companies · $4,436 in 2025
The $4,436 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,102 · 2020: $2,752 · 2021: $5,159 · 2022: $5,222 · 2023: $4,009 · 2024: $4,933 · 2025: $4,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,237.72 |
| Education | $139.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,979.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,711.03 | 2019-2025 | |
| Lilly USA, LLC | $1,706.12 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $1,243.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $1,004.39 | 2019-2025 | |
| Ucb, INC. | $963.18 | 2019-2025 | Fintepla, Zilbrysq, Rystiggo |
| Jazz Pharmaceuticals INC. | $874.47 | 2019-2024 | Epidiolex |
| Eisai INC. | $854.60 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $853.16 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $832.14 | 2021-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $795.59 | 2020-2025 | Xcopri |
| Supernus Pharmaceuticals, INC. | $759.17 | 2019-2024 | Qelbree |
| Genentech USA, INC. | $748.31 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Harmony Biosciences LLC | $748.06 | 2021-2025 | Wakix |
| Amgen INC. | $700.05 | 2019-2024 | Uplizna |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $689.86 | 2019-2025 | Nourianz |
| Csl Behring | $603.50 | 2022-2025 | Hizentra |
| Sunovion Pharmaceuticals INC. | $596.93 | 2020-2022 | |
| Emd Serono, INC. | $584.55 | 2019-2025 | Mavenclad |
| Janssen Pharmaceuticals, INC | $574.78 | 2020-2023 | Ponvory |
| Neurocrine Biosciences, INC. | $553.99 | 2019-2024 | Ingrezza, Ongentys |
| Avadel Cns Pharmaceuticals, LLC | $542.08 | 2024-2025 | Lumryz |
| Genzyme Corporation | $534.15 | 2019-2023 | |
| Greenwich Biosciences, INC. | $516.99 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $515.83 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Acorda Therapeutics, INC | $463.46 | 2019-2024 | Inbrija, Ampyra |
| E.R. Squibb & Sons, L.L.C. | $413.17 | 2021-2022 | |
| Mdd US Operations, LLC | $389.22 | 2019-2025 | Apokyn, Qelbree |
| Mallinckrodt Hospital Products INC. | $328.25 | 2020-2025 | Acthar |
| Argenx US, INC. | $322.40 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $318.35 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $301.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $290.15 | 2021 | |
| Axsome Therapeutics, INC. | $252.16 | 2023-2025 | Symbravo, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $240.63 | 2022-2025 | Hyqvia, Gammagard |
| Otsuka America Pharmaceutical, INC. | $231.33 | 2023-2024 | Rexulti |
| Acadia Pharmaceuticals INC | $228.61 | 2019-2024 | Nuplazid |
| Livanova USA, INC. | $175.08 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Insightec,INC | $166.18 | 2020 | |
| Horizon Therapeutics Plc | $165.43 | 2022 | |
| Adamas Pharmaceuticals, INC. | $161.69 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $136.01 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $122.78 | 2020-2023 | Firdapse |
| Abbott Laboratories | $120.78 | 2019-2024 | Infinity |
| Celgene Corporation | $118.94 | 2021-2025 | Zeposia |
| Currax Pharmaceuticals LLC | $115.84 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $98.72 | 2025 | Purified Cortrophin Gel |
| Ipsen Biopharmaceuticals, INC | $96.94 | 2019-2024 | Dysport |
| Avion Pharmaceuticals | $88.69 | 2022 | |
| Biogen, INC. | $75.14 | 2019-2022 | |
| Impel Pharmaceuticals LLC | $69.90 | 2025 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $68.42 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $64.33 | 2023 | Aptiom |
| Akcea Therapeutics, INC. | $63.59 | 2019-2020 | |
| Neurelis, INC. | $61.05 | 2024-2025 | Valtoco |
| Mallinckrodt Enterprises LLC | $56.40 | 2019 | |
| Promius Pharma LLC | $50.20 | 2019 | |
| Tonix Medicines, INC. | $44.74 | 2025 | Zembrace Symtouch |
| Impel Pharmaceuticals INC. | $39.86 | 2023 | Trudhesa |
| Kedrion Biopharma, INC. | $36.54 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Boston Scientific Corporation | $34.14 | 2021-2023 | |
| Medtronic, INC. | $27.38 | 2022 | |
| Avanir Pharmaceuticals, INC. | $22.61 | 2019 | |
| Inspire Medical Systems, INC. | $22.48 | 2024 | Inspire |
| Grifols USA, LLC | $14.52 | 2023 | Gamunex-C |
| Assertio Therapeutics, INC. | $14.27 | 2019 | |
| Mission Pharmacal Company | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grazyna Piekos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.